TY - JOUR
T1 - Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease
T2 - A Randomized Controlled Trial
AU - Hoffmann, Kristine
AU - Sobol, Nanna A
AU - Frederiksen, Kristian S
AU - Beyer, Nina
AU - Vogel, Asmus
AU - Vestergaard, Karsten
AU - Brændgaard, Hans
AU - Gottrup, Hanne
AU - Lolk, Annette
AU - Wermuth, Lene
AU - Jacobsen, Sø
AU - Laugesen, Lars P
AU - Gergelyffy, Robert G
AU - Høgh, Peter
AU - Bjerregaard, Eva
AU - Andersen, Birgitte B
AU - Siersma, Volkert
AU - Johannsen, Peter
AU - Cotman, Carl W
AU - Waldemar, Gunhild
AU - Hasselbalch, Steen G
PY - 2016
Y1 - 2016
N2 - BACKGROUND: Studies of physical exercise in patients with Alzheimer's disease (AD) are few and results have been inconsistent.OBJECTIVE: To assess the effects of a moderate-to-high intensity aerobic exercise program in patients with mild AD.METHODS: In a randomized controlled trial, we recruited 200 patients with mild AD to a supervised exercise group (60-min sessions three times a week for 16 weeks) or to a control group. Primary outcome was change from baseline in cognitive performance estimated by Symbol Digit Modalities Test (SDMT) in the intention-to-treat (ITT) group. Secondary outcomes included changes in quality of life, ability to perform activities of daily living, and in neuropsychiatric and depressive symptoms.RESULTS: The ITT analysis showed no significant differences between intervention and control groups in change from baseline of SDMT, other cognitive tests, quality of life, or activities of daily living. The change from baseline in Neuropsychiatric Inventory differed significantly in favor of the intervention group (mean: -3.5, 95% confidence interval (CI) -5.8 to -1.3, p = 0.002). In subjects who adhered to the protocol, we found a significant effect on change from baseline in SDMT as compared with the control group (mean: 4.2, 95% CI 0.5 to 7.9, p = 0.028), suggesting a dose-response relationship between exercise and cognition.CONCLUSIONS: This is the first randomized controlled trial with supervised moderate-to-high intensity exercise in patients with mild AD. Exercise reduced neuropsychiatric symptoms in patients with mild AD, with possible additional benefits of preserved cognition in a subgroup of patients exercising with high attendance and intensity.
AB - BACKGROUND: Studies of physical exercise in patients with Alzheimer's disease (AD) are few and results have been inconsistent.OBJECTIVE: To assess the effects of a moderate-to-high intensity aerobic exercise program in patients with mild AD.METHODS: In a randomized controlled trial, we recruited 200 patients with mild AD to a supervised exercise group (60-min sessions three times a week for 16 weeks) or to a control group. Primary outcome was change from baseline in cognitive performance estimated by Symbol Digit Modalities Test (SDMT) in the intention-to-treat (ITT) group. Secondary outcomes included changes in quality of life, ability to perform activities of daily living, and in neuropsychiatric and depressive symptoms.RESULTS: The ITT analysis showed no significant differences between intervention and control groups in change from baseline of SDMT, other cognitive tests, quality of life, or activities of daily living. The change from baseline in Neuropsychiatric Inventory differed significantly in favor of the intervention group (mean: -3.5, 95% confidence interval (CI) -5.8 to -1.3, p = 0.002). In subjects who adhered to the protocol, we found a significant effect on change from baseline in SDMT as compared with the control group (mean: 4.2, 95% CI 0.5 to 7.9, p = 0.028), suggesting a dose-response relationship between exercise and cognition.CONCLUSIONS: This is the first randomized controlled trial with supervised moderate-to-high intensity exercise in patients with mild AD. Exercise reduced neuropsychiatric symptoms in patients with mild AD, with possible additional benefits of preserved cognition in a subgroup of patients exercising with high attendance and intensity.
U2 - 10.3233/JAD-150817
DO - 10.3233/JAD-150817
M3 - Journal article
C2 - 26682695
SN - 1387-2877
VL - 50
SP - 443
EP - 453
JO - Journal of Alzheimer's disease : JAD
JF - Journal of Alzheimer's disease : JAD
IS - 2
ER -